Arrowhead Pharmaceuticals (ARWR) Interest Expenses (2011 - 2026)

Arrowhead Pharmaceuticals' Interest Expenses history runs 16 years deep, the most recent figure standing at $165.7 million for Q1 2026.

• Quarterly Interest Expenses rose 665.61% year-over-year to $165.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165.7 million (up 228.22% YoY) and the FY2025 annual result came in at $89.4 million, down 80.09% from the prior year.
• Interest Expenses was $165.7 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $169.6 million in the prior quarter.
• Across five years, Interest Expenses topped out at $177.0 million in Q2 2025 and bottomed at -$10.9 million in Q3 2023.
• A 5-year average of $42.4 million and a median of $5.1 million in 2024 frame the typical range for Interest Expenses.
• Peak annual rise in Interest Expenses reached 8565.71% in 2023, while the deepest fall reached 739.06% in 2023.
• Arrowhead Pharmaceuticals' Interest Expenses stood at $2.8 million in 2022, then jumped by 88.38% to $5.4 million in 2023, then soared by 303.32% to $21.6 million in 2024, then soared by 683.58% to $169.6 million in 2025, then decreased by 2.32% to $165.7 million in 2026.
• Business Quant data shows ARWR's Interest Expenses at $165.7 million in Q1 2026, $169.6 million in Q4 2025, and -$4.3 million in Q3 2025.